Clinical and economic evaluation of the impact of methicillin resistance on prosthetic joint infections

Yıl 2025, Cilt: 50 Sayı: 3, 617 - 623, 30.09.2025

Fatma Yekta Urkmez , Süleyman Kaan Öner , Sevil Alkan , Süleyman Kozlu

https://doi.org/10.17826/cumj.1647523

https://izlik.org/JA82LP78JK

Öz

Purpose: Prosthetic joint infection (PJI) is unfortunately a costly process. In this study, we aimed to examine the effect of methicillin resistance on the cost of PJI compared to susceptible patients.
Materials and Methods: Patients who underwent primary hip or knee arthroplasty in our center between January 2012 and December 2021 and were diagnosed with staphylococcal PJI were included in this retrospective design study. Expenses incurred during hospitalization were divided into categories. Each expense was converted to dollars ($) at the annual average exchange rate.
Results: A total of 55 patients were included in the study. There were 31 and 24 patients in the methicillin-resistant and susceptible groups, respectively. The methicillin-resistant group was significantly older than the susceptible group, other characteristics were similar. The cost in the methicillin-resistant group was $2055.7 ($676.0-$12620.0) and in the susceptible group was $1643.9 ($707.8-$10834.8). There was a statistically significant difference between the two groups in terms of surgical costs, antibiotic costs, blood center costs and radiology costs.
Conclusion: According to our study, the treatment cost of methicillin-resistant staphylococcus PJI was 1.3 times higher than that of methicillin-susceptible.

Anahtar Kelimeler

Primary arthroplasty , antimicrobial resistance , health expenditure , economic burden , cost

Metisilin direncinin protez eklem enfeksiyonlarına olan etkisinin klinik ve ekonomik sonuçlarının değerlendirmesi

https://izlik.org/JA82LP78JK

Öz

Amaç: Protez eklem enfeksiyonu (PEE) maalesef maliyetli bir süreçtir. Bu çalışmada metisilin direncinin PEE maliyetine olan etkisini duyarlı hastalarla karşılaştırmayı amaçladık.
Gereç ve Yöntem: Ocak 2012 ile Aralık 2021 arasında merkezimizde primer kalça veya diz artroplastisi geçiren ve stafilokok PJI tanısı alan hastalar çalışmaya dahil edildi. Hastanede yatış sırasında oluşan masraflar kategorilere ayrıldı. Her masraf yıllık ortalama döviz kuru üzerinden dolara ($) çevrildi.
Bulgular: Çalışmaya toplam 55 hasta dahil edildi. Metisiline dirençli ve duyarlı gruplarda sırasıyla 31 ve 24 hasta vardı. Sadece metisiline dirençli grubun yaşı duyarlı gruptan daha yüksekti, diğer özellikler benzerdi. Metisiline dirençli grupta maliyet 2055,7 $ (676,0-12620,0 $) ve duyarlı grupta 1643,9 $ (707,8-10834,8 $) idi. Bunun başlıca nedenleri cerrahi maliyetler, antibiyotik maliyetleri, kan merkezi maliyetleri ve radyoloji maliyetleriydi.
Sonuç: Çalışmamıza göre metisiline dirençli stafilokok PJI'nin tedavi maliyeti metisiline duyarlı olandan 1,3 kat daha yüksekti.

Anahtar Kelimeler

Primer artroplasti , antimikrobiyal direnç , sağlık harcaması , ekonomik yük , maliyet

Kaynakça

• Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-5.
• Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645-54.
• Urkmez FY, Yildiz F, Doganay M et al. Analysis of the cost of periprosthetic joint infections after total knee and hip arthroplasty and the effect of revision methods on the cost. Chir Narzadow Ruchu Ortop Pol. 2021;86:109-14.
• Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27:61-5.e1.
• ECDC, EFSA Panel on Biological Hazards (BIOHAZ), EMA Committee for Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA joint scientific opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. 2017;15:e05017.
• Barberán J, Aguilar L, Carroquino G, Giménez MJ, Sánchez B, Martínez D, Prieto J et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med. 2006;119:993.e7-10.
• Aggarwal VK, Bakhshi H, Ecker NU, Parvizi J, Gehrke T, Kendoff D. Organism profile in periprosthetic joint infection: pathogens differ at two arthroplasty infection referral centers in Europe and in the United States. J Knee Surg. 2014;27:399-406.
• Parvizi J, Ghanem E, Azzam K, Davis E, Jaberi F, Hozack W. Periprosthetic infection: are current treatment strategies adequate? Acta Orthop Belg. 2008;74:793-800.
• Carrega G, Casalino-Finocchio G, Cavagnaro L, Felli L, Riccio G, Burastero G. Long-term outcome of prosthetic joint infections treated with two-stage revision. Acta Orthop Belg. 2020;86:10-6.
• Viswanathan V, Pendsey S, Radhakrishnan C, Rege TD, Ahdal J, Jain R. Methicillin-resistant Staphylococcus aureus in diabetic foot infection in India: a growing menace. Int J Low Extrem Wounds. 2019;18:236-46.
• Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty. 2010;25:103-7.
• Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23:984-91.
• Premkumar A, Kolin DA, Farley KX et al. Projected economic burden of periprosthetic joint infection of the hip and knee in the United States. J Arthroplasty. 2021;36:1484-9.e3.
• Parvizi J, Zmistowski B, Berbari EF et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011;469:2992-4.
• Osmon DR, Berbari EF, Berendt AR et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1-25.
• Pettigrew M, Thirion DJ, Libman M, Zanotti G. Cost comparison of linezolid versus vancomycin for treatment of complicated skin and skin-structure infection caused by methicillin-resistant Staphylococcus aureus in Quebec. Can J Infect Dis Med Microbiol. 2012;23:187-95.
• Peel TN, Buising KL, Dowsey MM et al. Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother. 2013;57:350-5.
• Akindolire J, Morcos MW, Marsh JD, Howard JL, Lanting BA, Vasarhelyi EM. The economic impact of periprosthetic infection in total hip arthroplasty. Can J Surg. 2020;63:E52-6.
• Aftab MHS, Joseph T, Almeida R, Sikhauli N, Pietrzak JRT. Periprosthetic joint infection: a multifaceted burden undermining arthroplasty success. Orthop Rev (Pavia). 2025;17:138205.